VistaGen Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on September 9, 2025. During the meeting, stockholders elected six director nominees to the Board of Directors. Additionally, the compensation paid to the company's named executive officers was approved on a non-binding advisory basis. The appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending March 31, 2026, was also ratified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001411685-25-000081), on September 15, 2025, and is solely responsible for the information contained therein.